Evaluation of treatment-resistant schizophrenia

Schizophrenia Bulletin

Volumn 23, Issue 4, 1997, Pages 663-674

  Conley, Robert R ^a,b,c   Buchanan, Robert W ^a,b  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c Spring Grove Hospital Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; LITHIUM; OLANZAPINE; PROPRANOLOL; RESERPINE; RISPERIDONE; SERTINDOLE; VALPROIC ACID;

DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; TREATMENT PLANNING;

EID: 0030689616     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/schbul/23.4.663     Document Type: Review

References (103)

1. American Psychiatric Association. DSM-III: Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: The Association, 1980.
2. Arvanitis, L.A.; Miller, B.G.; and the Seroquel Trial 13 Study Group. "ICI 204,636: An Atypical Antipsychotic -Results From a Multiple Fixed-Dose, Placebo-Controlled Trial." Presented at the 32nd Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, May 1996.
3. Bak, T.H.; Bauer, M.; Schaub, R.T.; Hellweg, R.; and Reishiss, F.M. Myoclonis in patients treated with clozapine. Journal of Clinical Psychiatry, 56(9):418-422, 1995.
4. Baldessarini, R.J.; Cohen, B.M.; and Teicher, M. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45:79-91, 1988.
5. Barnes, T.R.E., and McEvedy, C.J.B. Pharmacological treatment strategies in the nonresponsive schizophrenic patient. International Clinical Psychopharmacology, 11(2):67-71, 1996.
6. Beasley, C.M.; Tollefson, G.; and Tran, P. Olanzapine versus placebo and haloperidol. Neuropsychopharmacology, 14:111-123, 1996.
7. Bellus, S.B.; Steward, D.; and Kost, P.P. Clozapine in aggression. [Letter] Psychiatric Services, 46(2):187, 1995.
8. Benatov, R.; Sirota, P.; and Megged, S. Neuroleptic-resistant schizophrenia treated with clozapine and ECT. Convulsive Therapy, 12(2):117-121, 1996.
9. Bilder, R.M.; Wu, H.; Chakos, M.H.; Bogerts, B.; Pollack, S.; Aronowitz, J.; Ashtari, M.; Degreef, G.; Kane, J.M.; and Lieberman, J.A. Cerebral morphometry and clozapine treatment in schizophrenia. Journal of Clinical Psychiatry, 55(Suppl. B):53-56, 1994.
10. Borison, R.L. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. Journal of Clinical Psychopharmacology, 15(Suppl. 1):24-29, 1995.
11. Breier, A.; Buchanan, R.W.; Irish, D.; and Carpenter, W.T., Jr. Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response patterns. Hospital and Community Psychiatry, 44(12):1145-1149, 1993.
12. Breier, A.; Buchanan, R.W.; Kirkpatrick, B.; Davis, O.R.; Irish, D.; Summerfelt, A.; and Carpenter, W.T., Jr. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry, 151(1):20-26, 1994.
13. Brenner, H.D.; Dencker, S.J.; Goldstein, M.J.; Hubbard, J.W.; Keegan, D.L.; Kruger, G.; Kulhanek, F.; Liberman, R.P.; Malm, U.; and Midha, K.K. Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin, 16(4):551-561, 1990.
14. Buckley, P.F., and Buchanan, R.W. Catching up on schizophrenia. Archives of General Psychiatry, 53:456-462, 1996.
15. Cardoni, A.A. Risperidone: Review and assessment of its role in the treatment of schizophrenia. Annals of Pharmacotherapy, 29(6):610-618, 1995.
16. Carman, J.S.; Bigelow, L.B.; and Wyatt, R.J. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. Journal of Clinical Psychiatry, 42:124-128, 1981.
17. Carpenter, W.T., Jr.; Conley, R.R.; Buchanan, R.W.; Breier, A.; and Tamminga, C.A. Patient response and resource management: Another view of clozapine treatment of schizophrenia. American Journal of Psychiatry, 152(6):827-832, 1995.
18. Chouinard, G.; Jones, B.; Remington, G.; Bloom, D.; Addington, D.; MacEwan, W.; LaBelle, A.; Beauclair, L.; and Arnott, W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13(1):25-39, 1993.
19. Chouinard, G.; Vainer, J.L.; Belanger, M.C.; Turnier, L.; Beaudry, P.; Roy, J.Y.; and Miller, R. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Progress in Neuropsychopharmacology and Biological Psychiatry, 18(7):1129-1141, 1994.
20. Christison, G.W.; Kirch, D.G.; and Wyatt, R.J. When symptoms persist: Choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin, 17(2):217-245, 1991.
21. Cohen, S.A., and Underwood, M.T. The use of clozapine in a mentally retarded and aggressive population. Journal of Clinical Psychiatry, 55(10):440-444, 1994.
22. Cohen, W.J., and Cohen, N.H. Lithium carbonate, haloperidol, and irreversible brain damage. Journal of the American Medical Association, 230:1283-1287, 1974.
23. Conley, R.R.; Carpenter, W.T., Jr.; and Tamminga, C.A. Time to response and response-dose in a 12-month clozapine trial. American Journal of Psychiatry, 154(9):1243-1247, 1997.
24. Conley, R.R.; Tamminga, C.A.; Satterlee, W.; and the Maryland Study Group. "Olanzapine vs. Chlorpromazine in Treatment-Resistant Schizophrenia." Presented at the Annual Meeting of the Society for Neuroscience, Washington, DC, November 1996.
25. Czobor, P.; Volavka, J.; and Meibach, R.C. Effect of risperidone on hostility in schizophrenia. Journal of Clinical Psychopharmacology, 15(4):243-249, 1995.
26. Davis, J.M., and Casper, R. Antipsychotic drugs: Clinical pharmacology and therapeutic use. Drugs, 12:260-282, 1977.
27. Delva, N.J., and Letemendia, F.J. Lithium treatment in schizophrenia and schizoaffective disorders. In: Kerr, A., and Snaith, P., eds. Contemporary Issues in Schizophrenia. London, England: Royal College of Psychiatrists, 1986. pp. 381-396.
28. Dencker, S.J., and Kulhanet, F., eds. Treatment Resistance in Schizophrenia. Braunschweig/Wiesbaden, Germany: Springer-Verlag, 1988.
29. Dixon, L.B.; Lehman, A.F.; and Levine, J. Conventional antipsychotic medications for schizophrenia. Schizophrenia Bulletin, 21(4):567-577, 1995.
30. Eronen, M.; Hakola, P.; and Tiihonen, J. Mental disorders and homicidal behavior in Finland. Archives of General Psychiatry, 53:497-501, 1996.
31. Essock, S.M.; Hargreaves, W.A.; Dohm, F.A.; Goethe, J.; Carver, L.; and Hipshman, L. Clozapine eligibility among State hospital patients. Schizophrenia Bulletin, 22(1):15-25, 1996.
32. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Archives of General Psychiatry, 49:538-544, 1992.
33. Frances, A.; Docherty, J.P.; and Kahn, D.A. The expert consensus guidelines series: Treatment of schizophrenia. Journal of Clinical Psychiatry, 57(12, Pt. B):11-50, 1996.
34. Freeman, T.W.; Clothier, J.L.; Pazzaglia, P.; Lesem, M.D.; and Swann, A.C. A double-blind comparison of valproate and lithium in the treatment of acute mania. American Journal of Psychiatry, 149:108-111, 1992.
35. Friedel, R.O. The combined use of neuroleptics and ECT in drug-resistant schizophrenic patients. Psychopharmacology Bulletin, 22(3):928-930, 1986.
36. Growe, G.A.; Crayton, J.W.; Klass, D.B.; Evans, H.; and Strizich, M. Lithium in chronic schizophrenia. American Journal of Psychiatry, 136:454-455, 1979.
37. Guy, W. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health, DHEW Publication No. (ADM)76-338, 1976.
38. Hanlon, T.E.; Ota, K.Y.; and Burland, A.A. Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide, and fluphenazine-imipramine. Disorders of the Nervous System, 31:171-177, 1970.
39. Herrera, J.N.; Sramek, J.J.; Costa, J.F.; Roy, S.; Heh, C.W.; and Nguyen, B.N. High-potency neuroleptics and violence in schizophrenics. Journal of Nervous and Mental Disease, 176(9):558-561, 1988.
40. Holden, J.M.; Itil, T.M.; Keskiner, A.; and Fink, M. Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia. Comprehensive Psychiatry, 9:633-643, 1968.
41. Janicak, P.G.; Davis, J.M.; Preskorn, S.H.; and Ayd, F.J., Jr. Principles and Practice of Psychopharmacotherapy. Baltimore, MD: Williams & Wilkins Company, 1993.
42. Johns, C.A., and Thompson, J.W. Adjunctive treatments in schizophrenia: Pharmacotherapies and electroconvulsive therapy. Schizophrenia Bulletin, 21(4):607-619, 1995.
43. Juarez-Reyes, M.G.; Shumway, M.; Battle, C.; Bacchetti, P.; Hansen, M.S.; and Hargreaves, W.A. Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatric Services, 46(8):801-806, 1995.
44. Kahn, E.M.; Schulz, S.C.; Perel, J.M.; and Alexander, J.E. Change in haloperidol level due to carbamazepine: A complicating factor in combined medication for schizophrenia. Journal of Clinical Psychiatry, 10:54-57, 1990.
45. Kane, J.M. Schizophrenia. New England Journal of Medicine, 334(1):34-41, 1996.
46. Kane, J.M.; Honigfeld, G.; Singer, J.; Meltzer, H.Y.; and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry, 45(9):789-796, 1988.
47. Kane, J.M., and Marder, S.R. Psychopharmacologic treatment of schizophrenia. Schizophrenia Bulletin, 19(2):113-128, 1993.
48. Kanter, G.L.; Yerevsanian, B.I.; and Ciccone, J.R. Case report of a possible interaction between neuroleptics and carbamazepine. American Journal of Psychiatry, 14:1101-1102, 1984.
49. Keck, P.E., Jr.; Wilson, D.R.; Strakowski, S.M.; McElroy, S.L.; Kizer, D.L.; Balistreri, T.M.; Holtman, H.M.; and DePriest, M. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. Journal of Clinical Psychiatry, 56(10):455-470, 1995.
50. Kinon, B.J.; Kane, J.M.; Johns, C.; Perovich, R.; Ismi, M.; Koreen, A.; and Weiden, P. Treatment of neuroleptic-resistant schizophrenia relapse. Psychopharmacology Bulletin, 29(2):309-314, 1993.
51. Kinon, B.J.; Kane, J.M.; Perovich, R.; Ismi, M.; and Koreen, A. "Influence of Neuroleptic Dose and Class in Treatment-Resistant Schizophrenia Relapse." Presented at the 32nd Annual Meeting of the New Clinical Drug Evaluation Unit, Key Biscayne, FL, May 1992.
52. Klein, D.F., and Davis, J.M. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, MD: Williams & Wilkins Company, 1969.
53. Klieser, E.; Lehmann, E.; Kinzler, E.; Wurthmann, C.; and Heinrich, K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. Journal of Clinical Psychopharmacology, 15(Suppl. 1):45-51, 1995.
54. Lacey, R.L.; Preskorn, S.H.; and Jerkovich, G.S. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics? [Letter] American Journal of Psychiatry, 152(9):1401, 1995.
55. 2 receptor selectivity of dopamine receptor antagonists: Possible therapeutic implications. European Journal of Pharmacology, 236(3):483-486, 1993.
56. Lieberman, J.A. Prediction of outcome in first-episode schizophrenia. Journal of Clinical Psychiatry, 54(Suppl.):13-17, 1993.
57. Lindstrom, E.; Eriksson, B.; Hellgren, A.; von Knorring, L.; and Eberhard, G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clinical Therapeutics, 17(3):402-412, 1995.
58. Lingjaerde, O.; Engstrand, E.; Ellingsen, P.; Stylo, D.A.; and Robak, O.H. Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients: A double-blind clinical trial. Current Therapeutic Research, 26:505-512, 1979.
59. Mallya, A.R.; Roos, P.D.; and Roebuck-Colgan, K. Restraint, seclusion, and clozapine. Journal of Clinical Psychiatry, 53:395-397, 1992.
60. Malone, M.L.; Thompson, L.; and Goodwin, J.S. Aggressive behavior among the institutionalized elderly. Journal of the American Geriatrics Society, 41(8):853-856, 1993.
61. Marder, S.R., and Meibach, R.C. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151:825-835, 1994.
62. McGlashan, T.H. A selective review of recent North American long-term followup studies of schizophrenia. Schizophrenia Bulletin, 14(4):515-542, 1988.
63. Meltzer, H.Y. Commentary: Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin, 16(4):563-565, 1990.
64. Meltzer, H.Y. New drugs for the treatment of schizophrenia. Psychiatric Clinics of North America, 16:365-385, 1993.
65. Meltzer, H.Y. An overview of the mechanism of action of clozapine. Journal of Clinical Psychiatry, 55(Pt. B):47-52, 1994.
66. Meltzer, H.Y.; Burnet, S.; Bastani, B.; and Ramirez, L.F. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry, 141:892-897, 1990.
67. Meltzer, H.Y., and Okayli, G. Reduction of suicidality during clozapine treatment in neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. American Journal of Psychiatry, 152:183-190, 1995.
68. Miller, F., and Menninger, J. Lithium-neuroleptic neurotoxicity is dose-dependent. Journal of Psychopharmacology, 7:89-91, 1987.
69. Ota, P.; Maeshiro, H.; Ishido, H.; Shimizu, Y.; Uchida, R.; Toyoshima, R.; Ohshima, H.; Takazawa, A.; Motomura, H.; and Noguchi, T. Treatment-resistant chronic psychopathology and CT scans in schizophrenia. Acta Psychiatrica Scandinavica, 75:415-427, 1987.
70. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale. Psychological Reports, 10:799-812, 1962.
71. Pato, C.N.; Wolkowitz, O.M.; Rapaport, M.; Schulz, S.C.; and Pickar, D. Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. Psychopharmacology Bulletin, 25(2):263-266, 1989.
72. Physicians' Desk Reference. Montvale, NY: Medical Economics Data Production Co., 1996.
73. Pickar, D.; Breier, A.; and Kelsoe, J. Plasma homovanillic acid as an index of central dopaminergic activity: Studies in schizophrenic patients. Annals of the New York Academy of Sciences, 537:339-346, 1988.
74. Pickar, D.; Owen, R.R.; Litman, R.E.; Konicki, E.; Gutierrez, R.; and Rapaport, M.H. Clinical and biologic response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine. Archives of General Psychiatry, 49(5):345-353, 1992.
75. Post, R.M. Non-lithium treatment for bipolar disorder. Journal of Clinical Psychiatry, 51(Suppl.):9-16, 1990.
76. Prien, R.F., and Cole, J.O. High-dose chlorpromazine therapy in chronic schizophrenia. Archives of General Psychiatry, 18(4):482-495, 1968.
77. Ratey, J.J.; Leveroni, C.; Kilmer, D.; Gutheil, C.; and Swartz, B. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. Journal of Clinical Psychiatry, 54(6):219-223, 1993.
78. Remington, G.J.; Addington, D.; Collins, E.J.; Jones, B.D.; Lalonde, P.; MacCrimmon, D.J.; and MacEwan, G.W. Clozapine: Current status and role in the pharmacotherapy of schizophrenia. Canadian Journal of Psychiatry, 41(3):161-166, 1996.
79. Revicki, D.A.; Luce, B.R.; Weschler, J.M.; Brown, R.E.; and Adler, M.A. Economic grand rounds: Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital and Community Psychiatry, 41(8):850-854, 1990.
80. Rifkin, A.; Quitkin, F.; Rabiner, C.J.; and Klein, D.F. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics: I. Relapse rates after one year. Archives of General Psychiatry, 34(1):43-47, 1977.
81. Ruskin, P.; Averbukh, I.; Belmaker, R.H.; and Dasberg, H. Benzodiazepines in chronic schizophrenia. Biological Psychiatry, 14:557-558, 1979.
82. Safferman, A.; Lieberman, J.A.; Kane, J.M.; Szymanski, S.; and Kinon, B. Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin, 17(2):247-261, 1991.
83. Schulz, S.C.; Kahn, E.M.; Baker, R.W.; and Conley, R.R. Lithium and carbamazepine augmentation in treatment-refractory schizophrenia. In: Angrist, B., and Schulz, S.C., eds. The Neuroleptic-Nonresponsive Patient: Characterization and Treatment. Washington, DC: American Psychiatric Press, 1990. pp. 109-136.
84. Seeman, P., and Van Tol, H.H. Dopamine receptor pharmacology. Current Opinion in Neurology and Neurosurgery, 6(4):602-608, 1993.
85. Shalev, A.; Hermesh, H.; Rothberg, J.; and Munitz, H. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica, 87:86-91, 1993.
86. Shore, D. Clinical implications of clozapine discontinuation: Report of an NIMH workshop. Schizophrenia Bulletin, 21(2):333-338, 1995.
87. Simhandl, C., and Meszaros, K. The use of carbamazepine in the treatment of schizophrenia and schizoaffective psychosis: A review. Journal of Psychiatry and Neuroscience, 17:1-14, 1992.
88. Small, J.G. Efficacy of electroconvulsive therapy in schizophrenia, mania, and other disorders: I. Schizophrenia. Convulsive Therapy, 1:263-270, 1985.
89. Small, J.G.; Kellams, J.J.; Milstein, V.; and Moore, J. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. American Journal of Psychiatry, 132:1315-1317, 1975.
90. Stern, R.G.; Kahn, R.S.; and Davidson, M. Predictors of response to neuroleptic treatment in schizophrenia. Psychiatric Clinics of North America, 16(2):313-338, 1993.
91. Tamminga, C.A.; Mack, R.; Silber, C.J.; and Kashkin, K.B. Sertindole in the treatment of psychosis in schizophrenia: Efficacy and safety. International Clinical Psychopharmacology, in press.
92. Tamminga, C.A.; Thaker, G.K.; Moran, M.; Kakigi, T.; and Gao, X.M. Clozapine in tardive dyskinesia: Observations from human and animal model studies. Journal of Clinical Psychiatry, 55(Suppl. B):102-106, 1994.
93. Terkelsen, K.G., and Grosser, R.C. Estimating clozapine's cost to the nation. Hospital and Community Psychiatry, 41(8):863-869, 1990.
94. van Kammen, D.P., and Schooler, N. Are biochemical markers for treatment-resistant schizophrenia state dependent or traits? Clinical Neuropharmacology, 13(1):516-528, 1990.
95. Van Putten, T.; Marder, S.R.; and Mintz, J. A controlled-dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry, 47:754-758, 1990.
96. Volavka, J.; Zito, J.M.; Vitrai, J.; and Czobar, P. Clozapine effects on hostility and aggression in schizophrenia. [Letter] Journal of Clinical Psychopharmacology, 13(4):287-289, 1993.
97. Wilson, W.H. Clinical review of clozapine treatment in a state hospital. Hospital and Community Psychiatry, 43:700-703, 1992.
98. Wolkin, A.; Barouche, F.; Wolf, A.P.; Rotrosen, J.; Fowler, J.S.; Shiue, C.Y.; Cooper, T.B.; and Brodie, J.D. Dopamine blockade and clinical response: Evidence for two biological subgroups of schizophrenia. American Journal of Psychiatry, 146:905-908, 1989.
99. Wolkowitz, O.M.; Pickar, D.; Doran, A.R.; Breier, A.; Tarell, J.; and Paul, S.M. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. American Journal of Psychiatry, 143:85-87, 1986.
100. Wolkowitz, O.M.; Turetsky, N.; Reus, V.I.; and Hargreaves, W.A. Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. Psychopharmacology Bulletin, 28(3):291-295, 1992.
101. Yerevanian, B.I., and Hodgman, C.H. A haloperidol-carbamazepine interaction in a patient with rapid-cycling bipolar disorder. [Letter] American Journal of Psychiatry, 142(6):785-786, 1985.
102. Zimbroff, D.L.; Kane, J.M.; Tamminga, C.A.; Daniel, D.G.; Mack, R.J.; Wozniak, P.J.; Sebree, T.B.; Wallin, B.A.; Kashkin, K.B.; and the Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry, 154:782-791, 1997.
103. Zito, J.M.; Volavka, J.; Craig, T.J.; Czobor, P.; Banks, S.; and Vitrai, J. Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia. Annals of Pharmacotherapy, 27:1262-1269, 1993.